Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
Tollys and Gustave Roussy enter into new research agreement
Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer
Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting
Robocath and Rennes University Hospital launch co-development research program into treatment of strokes in partnership with Philips France
Yposkesi accueille le groupe SK comme nouvel actionnaire majoritaire à son capital et noue ainsi un solide partenariat industriel de croissance
Noventure signs exclusive license agreement for innovative food supplement EPA3G
• EPA3G a unique, patented emulsion of high purity EPA, in drinkable single sachet – containing daily dose of 3g
• Deal gives Noventure licensing rights in over 50 countries
• Agreement signed with global partner Azur Global Nutrition
